Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C

Shinya Maekawa,Mitsuaki Sato,Natsuhiko Kuratomi,Taisuke Inoue,Yuichiro Suzuki,Akihisa Tatsumi,Mika Miura,Shuya Matsuda,Masaru Muraoka,Natsuko Nakakuki,Fumitake Amemiya,Shinichi Takano,Mitsuharu Fukasawa,Yasuhiro Nakayama,Tatsuya Yamaguchi,Tadashi Sato,Minoru Sakamoto,Miyako Murakawa,Mina Nakagawa,Yasuhiro Asahina,Nobuyuki Enomoto

Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C

2018

Background Liver damage presented as alanine aminotransferase (ALT) elevation and high ALT-caused treatment discontinuation occurs with high frequency in Japanese patients receiving daclatasvir plus asunaprevir (DCV/ASV) therapy for hepatitis C virus (HCV) infection, and its mechanism is unknown.

Keywords:

Elevation
Hepatitis C virus
Hepatitis C
Discontinuation
Combination therapy
Alanine
Daclatasvir
Asunaprevir
Virology
Medicine
chronic hepatitis
alanine aminotransferase
General surgery
Internal medicine
Diabetes mellitus
Gastroenterology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations